Announcement no. 5/2008
To OMX The Nordic Exchange Copenhagen and the press
Copenhagen, January 31, 2008
Exiqon A/S announces financial calendar for 2008
Below are the expected dates for Exiqon A/S' annual general meeting and
financial reporting in 2008
Financial Calendar
--------------------------------------------------------------------------------
| Announcement of full-year results 2007: 12 March 2008 |
--------------------------------------------------------------------------------
| The annual general meeting is scheduled to be held on: | 2 April 2008 |
--------------------------------------------------------------------------------
| Interim report for the period 1 January 2008 to 31 | 15 May 2008 |
| March 2008: | |
--------------------------------------------------------------------------------
| Interim report for the period 1 January 2008 to 30 | 28 August 2008 |
| June 2008: | |
--------------------------------------------------------------------------------
| Interim report for the period 1 January 2008 to 30 | 26 November 2008 |
| September 2008: | |
--------------------------------------------------------------------------------
For more information, please contact:
Lars Kongsbak, President and CEO, tel. + 45 40 90 21 01
Hans Henrik Chrois Christensen, CFO, tel. +45 45 65 09 53 or + 45 40 90 21 31
About Exiqon
Exiqon's corporate mission is to combine leading-edge scientific expertise in
gene expression with our proprietary LNA™ technology. Exiqon's products,
services and scientific staff enable life science researchers to make
groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a
new approach to the diagnosis of cancer. Exiqon's products are based on patented
technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and
sensitive analysis of nucleic acids. Exiqon aims to expand the existing product
offering for research use as well as to develop new proprietary molecular
diagnostic products. Exiqon, through a number of recent initiatives, has
positioned itself as a significant player in applying miRNA as the key biomarker
in cancer diagnostics.
Disclaimer
Forward-looking statements:
This announcement contains forward-looking statements regarding Exiqon's
potential future development and financial performance and other statements
which are not historical facts. Such statements are made on the basis of
assumptions and expectations which, to the best of Exiqon's knowledge, are
reasonable and well-founded at this time, but which may prove to be erroneous.
Exiqon's operations are characterized by the fact that its actual results may
deviate significantly from that described herein as anticipated, believed,
estimated or expected.
This announcement is not an offer of securities for sale in Exiqon. The shares
in Exiqon have not been registered under the U.S. Securities Act of 1933, as
amended (the “Securities Act”) or any State securities laws and may not be
offered, sold or delivered within the United States or to U.S. persons absent
from registration under or an applicable exemption from the registration
requirements of the United States securities laws and applicable State
securities laws.